Dravet syndrome

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

10 events
Jun 2026A Study to Investigate the Transition of Children From 'Artisanal" Cannabidiol (CBD) to Epidiolex

Elizabeth Donner — PHASE4

TrialNOT YET RECRUITING
Dec 2025Clinical Utility of Reduced EEG Home Monitoring in Fenfluramine Titration for Dravet and LGS

Byteflies — NA

TrialNOT YET RECRUITING
Sep 2025Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation

Assistance Publique - Hôpitaux de Paris

TrialRECRUITING
Jun 2025A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

Stoke Therapeutics, Inc — PHASE3

TrialRECRUITING
Oct 2024Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age

University of Colorado, Denver — PHASE4

TrialRECRUITING
Sep 2024A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

Longboard Pharmaceuticals — PHASE3

TrialRECRUITING
May 2024A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome

UCB BIOSCIENCES, Inc. — PHASE3

TrialACTIVE NOT RECRUITING
May 2024A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome

Encoded Therapeutics — PHASE1, PHASE2

TrialRECRUITING
May 2024A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome

Encoded Therapeutics — PHASE1, PHASE2

TrialACTIVE NOT RECRUITING
Feb 2024A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)

Encoded Therapeutics — PHASE1, PHASE2

TrialACTIVE NOT RECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

1

Copay cards

Copay Assistance1

Diacomit

Biocodex

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

3 FDA-approved

Diacomit

(stiripentol)Orphan drug

Biocodex

Approved Jul 2022

Fintepla

(fenfluramine)Orphan drugstandard

UCB, Inc.

12.1 Mechanism of Action The precise mechanism by which fenfluramine exerts its therapeutic effects in the treatment of seizures associated with Drave...

FDA label ↗

Epidiolex

(CANNABIDIOL)Orphan drugstandard

Jazz Pharmaceuticals, Inc.

12.1 Mechanism of Action The precise mechanisms by which EPIDIOLEX exerts its anticonvulsant effect in humans are unknown. Cannabidiol does not appear...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

12 active trials
4Phase 3
1Phase 4
1Phase 2
1N/A
2Unknown
3PHASE1, PHASE2
12Total recruiting
Search clinical trials for Dravet syndrome

Recent News & Research

1 article
EpilepsiaMar 26, 2026

Underutilization of syndrome-specific ICD-10 codes for genetic epilepsies: Implications for precision medicine

Published in Epilepsia. Moura Coelho da Silva É et al.

Read ↗

Browse all Dravet syndrome news →

Specialist Network

Top 6 by expertise

View all Dravet syndrome specialists →

Quick Actions